Brazilian Thalassemia Association protocol for iron chelation therapy in patients under regular transfusion

Revista Brasileira de Hematologia e Hemoterapia

Monica Pinheiro De Almeida Verissimo¹  Sandra Regina Loggetto¹  Antonio Fabron Junior¹  Giorgio Roberto Baldanzi¹  Nelson Hamerschlak¹  Juliano Lara Fernandes¹  Aderson Da Silva Araujo¹  Clarisse Lopes De Castro Lobo¹  Kleber Yotsumoto Fertrin¹  Vasilios Antonios Berdoukas¹  Renzo Galanello¹ 

关键词: Blood transfusion;    Chelation therapy;    Deferiprone;    Deferasirox;    Iron/metabolism;    beta-Thalassemia;    Iron overload;    Iron chelating agents;    Magnetic resonance imaging;    Practice guidelines as topic;    Protocols;    Brazil;   

DOI  :  10.5581/1516-8484.20130106

来源: SciELO

【 摘 要 】

In the absence of an iron chelating agent, patients with beta-thalassemia on regular transfusions present complications of transfusion-related iron overload. Without iron chelation therapy, heart disease is the major cause of death; however, hepatic and endocrine complications also occur. Currently there are three iron chelating agents available for continuous use in patients with thalassemia on regular transfusions (desferrioxamine, deferiprone, and deferasirox) providing good results in reducing cardiac, hepatic and endocrine toxicity. These practice guidelines, prepared by the Scientific Committee of Associação Brasileira de Thalassemia (ABRASTA), presents a review of the literature regarding iron overload assessment (by imaging and laboratory exams) and the role of T2* magnetic resonance imaging (MRI) to control iron overload and iron chelation therapy, with evidence-based recommendations for each clinical situation. Based on this review, the authors propose an iron chelation protocol for patients with thalassemia under regular transfusions.

【 授权许可】

CC BY-NC-ND   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License